Table 1.

Characteristics of the study population by hypertension classification as defined by median midweek intradialytic BP

SNWCHMHTNSHTNTotalP
n123 (35%)52 (15%)54 (15%)124 (35%)353 (100%)
Men82 (67%)32 (62%)38 (70%)76 (61%)228 (65%)0.61
Race0.03
    nonblack14 (11%)5 (10%)15 (28%)21 (17%)55 (16%)
    black109 (89%)47 (90%)39 (72%)103 (83%)298 (84%)
Age (years)55.7 ± 14.055.6 ± 12.556.5 ± 13.354.1 ± 11.755.2 ± 12.90.63
Body mass index (kg/m2)28.4 ± 5.828.8 ± 7.326.5 ± 5.827.1 ± 5.427.7 ± 5.90.07
Etiology of end-stage renal disease0.20
    diabetes mellitus41 (33%)21 (40%)24 (44%)45 (36%)131 (37%)
    hypertensive nephrosclerosis57 (46%)23 (44%)21 (39%)51 (41%)152 (43%)
    glomerulonephritis9 (7%)0 (0%)0 (0%)11 (9%)20 (6%)
    adult autosomal polycystic kidney disease1 (1%)1 (2%)0 (0%)3 (2%)5 (1%)
    other/unknown9 (7%)4 (8%)8 (15%)9 (7%)30 (8%)
Years on dialysis4.7 ± 4.92.9 ± 2.63.7 ± 4.63.0 ± 3.43.7 ± 4.1<0.01
History of smoking0.55
    current33 (27%)14 (27%)13 (24%)45 (36%)105 (30%)
    past46 (37%)17 (33%)18 (33%)41 (33%)122 (35%)
    never41 (33%)16 (31%)22 (41%)37 (30%)116 (33%)
History of diabetes mellitus54 (44%)26 (50%)33 (61%)61 (49%)174 (49%)0.22
History of cardiovascular disease40 (33%)21 (40%)22 (41%)42 (34%)125 (35%)0.62
Urea reduction ratio (%)73.9 ± 7.873.6 ± 8.474.3 ± 6.374.4 ± 7.474.1 ± 7.50.97
Albumin (g/dl)3.7 ± 0.43.8 ± 0.43.7 ± 0.43.7 ± 0.53.7 ± 0.40.10
Hemoglobin (g/dl)12.3 ± 1.612.3 ± 1.512.2 ± 1.511.9 ± 1.412.2 ± 1.50.22
On antihypertensive medications77 (63%)41 (79%)48 (89%)102 (82%)268 (76%)<0.01
Number of antihypertensives in users1.3 ± 1.31.9 ± 1.42.5 ± 1.62.3 ± 1.61.9 ± 1.6<0.01
    β-blocker66 (54%)33 (63%)37 (69%)88 (71%)224 (63%)0.03
    ACE inhibitor38 (31%)16 (31%)29 (54%)64 (52%)147 (42%)<0.01
    ARB8 (7%)6 (12%)9 (17%)16 (13%)39 (11%)0.21
    α-blocker4 (3%)5 (10%)4 (7%)10 (8%)23 (7%)0.31
    dihydropyridine calcium-channel blocker29 (24%)21 (40%)29 (54%)64 (52%)143 (41%)<0.01
    non-dihydropyridine calcium-channel blocker2 (2%)2 (4%)4 (7%)6 (5%)14 (4%)0.30
    vasodilator19 (15%)7 (13%)12 (22%)17 (14%)55 (16%)0.45
    centrally acting agents15 (12%)15 (29%)15 (28%)40 (32%)85 (24%)<0.01
Interdialytic weight gain (kg)2.9 ± 1.22.7 ± 1.22.8 ± 1.22.7 ± 1.32.8 ± 1.20.87
  • SN, sustained normotension; WCH, white-coat hypertension; MHTN, masked hypertension; SHTN, sustained hypertension; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.